News

Researchers at the Queen’s University Belfast developed a new compound that may change how lung ailments in cystic fibrosis (CF) are treated. The potential medicine was shown in an early study to improve airway hydration and increase mucus clearance, results that suggest a mechanism to potentially delay or prevent lung disease independently of the…

AbbVie welcomes undergraduate and graduate students with cystic fibrosis (CF) to apply for the 2016 AbbVie CF Scholarship, awarding $3,000 for education-related expenses. Applications will be accepted until May 27 and are available online at www.AbbVieCFScholarship.com. The CF community in the U.S. includes approximately 30,000 children and adults, and about half…

Galapagos NV recently announced the start of a Phase 1 clinical trial to address the safety and tolerability of its potentiator candidate, GLPG2451, to treat cystic fibrosis (CF). CF is caused by mutations in the CFTR gene that lead to an abnormal transport of chloride across cell membranes, resulting in defective hydration of…

International Biophysics Corporation recently announced the publication of new data regarding the effectiveness of its AffloVest airway clearance technology in patients with cystic fibrosis. The paper, “Lung function improvement with AffloVest® HFCWO use: a clinician’s perspective on PFT score data from 12 patients with cystic fibrosis,” was published on the…

People whose cystic fibrosis was detected through screening programs for newborns were found to have better growth throughout puberty and superior adult height, compared to those whose CF was diagnosed after they began exhibiting symptoms, researchers at the University of Wisconsin–Madison reported. The study, based on analyzed data from the Wisconsin Randomized Clinical Trial, “Pubertal Height…

Researchers at the University of Pittsburgh Center for Vaccine Research (CVR) have developed an engineered antimicrobial peptide effective against co-infection by bacterial microfilm and a virus, and as such is a possible new therapeutic agent against chronic and antibiotic-resistant infections. Importantly, the potential drug was tested against Pseudomonas aeruginosa, one of the primary and more dangerous…

Newborn screening programs for cystic fibrosis (CF) are in wide use, but recent improvements in readily available therapies for young children have raised the question of whether such screening is still of benefit. In the study, “The benefits of newborn screening for cystic fibrosis: The Canadian experience,” published in…

In the cystic fibrosis (CF) community, May is an important month — one set aside by the Cystic Fibrosis Foundation to educate and raise awareness across the U.S. of the disease and its impact on people’s lives as part of National CF Awareness Month. Among these efforts is a highly visible window display…

The Cystic Fibrosis Foundation, a leading supporter of research funding for new cystic fibrosis (CF) treatments with the goal of finding a cure, announced the appointment of Marc Ginsky as its new executive vice president and chief operating officer. Ginsky will report to the organization’s president and chief executive officer, Dr.

Galapagos NV and AbbVie recently expanded their collaborative agreement in cystic fibrosis (CF) to mirror the successful growth of their CF portfolio, with an ultimate goal of developing a triple combination therapy able to treat 90 percent of all cystic fibrosis patients. Triple combinations of CF compounds already in the companies’…